⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
globenewswire.com
NTHI
CNTB
VBIO
LLY
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
prnewswire.com
LLY
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
prnewswire.com
LLY
Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma
prnewswire.com
LLY
Global Drug Discovery Informatics Market (2026-2031) - Advancements in AI and Machine Learning Accelerate Growth
globenewswire.com
TMO
DSY
SRG
CTRA
IBM
INFY
CHTR
NVDA
LLY
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
prnewswire.com
LLY
CytoHub Co-Founder Aitor Aguirre Named to Lead Cardiac Tissue Engineering at NIH's First National Organoid Center
businesswire.com
JNJ
SNY
LLY
NVDA
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
prnewswire.com
LLY
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
prnewswire.com
LLY
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
prnewswire.com
LLY
RVMD
ONCY
AMGN
VSTM